Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey

Despite the size of the ever-growing inflammatory bowel disease (IBD) drug market and its diversity of modalities from JAK inhibitors to IL-23s, unmet needs and treatment gaps remain.  | A survey of 36 U.S. gastroenterologists found that significant treatment gaps remain in the growing IBD drug market despite an expanding range of therapies.